Litcius/Paper detail

Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3.

Jeong‐Yub Kim, Yunhui Jo, Hoon Kyu Oh, Eun Ho Kim

2020PubMed22 citationsOpen Access PDF

Abstract

silencing can also be accomplished by RNA interference and can increase the TTFields-sensitizing effect of sorafenib. If the effects are reversed and gene regulating STAT3 is expressed more, it annihilates the effects of treatment. Moreover, sorafenib plus TTFields significantly inhibited xenograft tumor growth and combinatorial treatment reduced STAT3 expression more effectively in vivo. These in vitro and in vivo results indicate that sorafenib tends to sensitize GBM cells to TTFields-induced apoptosis by inhibiting STAT3.

Topics & Concepts

SorafenibSTAT3SurvivinIn vivoCancer researchApoptosisU87Gene silencingmicroRNAMedicineSTAT proteinChemistryBiologyGlioblastomaGeneHepatocellular carcinomaBiochemistryBiotechnologyGlioma Diagnosis and TreatmentCancer Mechanisms and TherapyMicrotubule and mitosis dynamics
Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3. | Litcius